Features Introduction

• Product development and analysis of Synmosa's unique technological platform of HFA MDI (Metered Dose Inhaler) complies with the latest international regulatory requirements. Synmosa HFA MDI Platform upholds the key features for the efficacy of MDI: including API, HFA propellant, excipients, canister, metering valve and actuator.
• MDI manufacturing technology has high barrier of entry, Synmosa is the only manufacturer of its kind in Taiwan. Self-developed patented process and formulation with the low-ethanol technology shows superiority in aspect of less excipients used, excellent content uniformity, and good stability. Both manufacturing process and formulation has patent in Taiwan, Singapore, China, United States, Canada, New Zealand, Australia, South Korea, and Hong Kong.

The only HFA MDI Production R&D platform in Taiwan